Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 3/20 | 0.61 |
| ▸ | EGFR | P00533 | 3/20 | 0.58 |
| ▸ | SRC | P12931 | 5/20 | 0.56 |
| ▸ | MAP3K7 | O43318 | 6/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.55 |
| ▸ | MAPK3 | P27361 | 3/20 | 0.55 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.53 |
| ▸ | FLT3 | P36888 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23606823 | 0.94 | MAPK3 (0.54) | JAK3EGFRSRCMAP3K7MAPK1 | |
| SCHEMBL30331238 | 0.94 | MAPK3 (0.54) | JAK3EGFRSRCMAP3K7MAPK1 | |
| SCHEMBL30044417 | 0.93 | ALK (0.60) | JAK3EGFRSRCMAP3K7MAPK1 | |
| SCHEMBL30045121 | 0.93 | ALK (0.56) | JAK3EGFRSRCMAP3K7FGFR1 | |
| SCHEMBL25139826 | 0.93 | ALK (0.56) | JAK3EGFRSRCMAP3K7FGFR1 | |
| SCHEMBL25139831 | 0.93 | ALK (0.60) | JAK3EGFRSRCMAP3K7MAPK1 | |
| SCHEMBL25140070 | 0.92 | JAK3 (0.54) | JAK3EGFRSRCMAP3K7MAPK1 | |
| SCHEMBL25139771 | 0.90 | PLK1 (0.60) | JAK3EGFRFGFR1MAPK3 | |
| SCHEMBL25139800 | 0.90 | PLK1 (0.55) | JAK3EGFRSRCFGFR1MAPK3 | |
| SCHEMBL30043654 | 0.90 | PLK1 (0.60) | JAK3EGFRFGFR1MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED (CN) | 2023-04-20 | — | — | US | disclosed |
| CN-113087671-B | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | 北京赛特明强医药科技有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-113087671-A | Cyano-substituted pyridine and cyano-substituted pyrimidine compounds, and preparation methods and applications thereof | 北京赛特明强医药科技有限公司 | 2021-07-09 | — | — | CN | disclosed |
| WO-2021129561-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021129561-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 北京赛特明强医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230125046-A1 | CYANO-SUBSTITUTED PYRIDINE AND CYANO-SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | FGFR4, FGFR1, WEE1 | JAK3 372/4885EGFR 561/4885SRC 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.